Capstan Therapeutics presents preclinical data on lead in vivo CAR-T candidate, CPTX2309, with plans to advance into the ...

The sFlt-1/PlGF ratio did not effectively gauge future preeclampsia risk in pregnant patients with SLE and proteinuria.

At this year's American College of Rheumatology (ACR) annual meeting, HSS presented several significant studies, with three focused on reproductive health: infant feeding behaviors among women with ...

Substantial improvements in ultrasound technology and expanded use of it have necessitated an update of the 2012 ...

Prediction of histologically active LN was also highly accurate by other measures, he reported at the American College of ...

Fate Therapeutics (FATE) stock rallied 37% Monday on positive Phase 1 study data for its cell therapies FT819 and FT522. Read ...

The presentation entitled, " Safety and Efficacy Data from a Phase I Trial of Umbilical Lining Stem Cells (ULSCs) in Adult ...

One of the key drivers behind the stock’s impressive jump is the recent presentation of initial clinical and translational data from the company’s ongoing FT819 Phase 1 Autoimmunity study at the ...

With baseline KOOS values averaging about 46, sham and real PT were equally effective, separated by less than 1 KOOS point, ...

CABA-201 safety profile suggests favorable risk-benefit with no CRS or ICANS in the majority of patients; low-grade CRS in three of eight ...

Participation in the RISE registry is linked to improved performance on key rheumatology quality measures, as revealed by an ...

Phase 1 Basket Study for B Cell-mediated Autoimmune Diseases to Assess FT522 as Add-on to Standard-of-care Induction and Maintenance Regimens ...